1. Scrip
  2. >>Leadership

Decisions That Made A Difference: Wockhardt Chief On A Life In Business

 
• By Anju Ghangurde

Dr Habil Khorakiwala, Wockhardt’s chair and group CEO, recounts his life and business journey, including an acquisition that went wrong, in an interview with Scrip as part of our ongoing executive profile series. Khorakiwala also outlines where he sees Wockhardt in the coming years, with the firm’s R&D thrust in the antibiotics space expected to play a pivotal role.

Habil Khorakiwala
WOCKHARDT CHAIR AND GROUP CEO DR HABIL KHORAKIWALA

Wockhardt’s founder chair and group CEO, Dr Habil Khorakiwala, believes learning from mistakes is as important as cherishing success. He has been candid enough to discuss with Scrip some of the troughs, as well as the peaks, along the corporate journey that has seen Wockhardt Ltd. emerge as a prominent Indian firm with sales of INR40.15bn ($630m) for the year ended March 2017.

In the latest instalment of our ongoing executive profile series, Khorakiwala recalls the early challenges around getting Worli Chemical Works (as the company was previously known) running and why the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

More from Scrip

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.